Riociguat

Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

Product Specifications

CAS Number

[625115-55-1]

Product Name Alternative

BAY 632521

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Guanylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Riociguat.html

Purity

99.80

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=CC=C1CN2C3=NC=CC=C3C(C4=NC(N)=C(C(N)=N4)N(C)C(OC)=O)=N2

Molecular Formula

C20H19FN8O2

Molecular Weight

422.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Schermuly RT, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32 (4) :881-91.|[2]Schermuly RT, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs. 2011 Apr;20 (4) :567-76.|[3]Donda K, et al. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth. PLoS One. 2018 Jul 10;13 (7) :e0199927.